Sanofi and Orano join forces to develop next-generation …
4 days ago · Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines. Building on the expertise and radioligand ...
Sanofi and Orano Join Forces to Develop Next-generation …
4 days ago · Julien Dodet President of the Governing Board, Orano Med “Sanofi’s partnership with Orano Med is a strong recognition of the potential of lead-212 based radioligand therapies to advance the ...
Press Release: Sanofi and Orano join forces to develop next …
4 days ago · Sanofi and Orano join forces to develop next-generation radioligand medicines. Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate ...
Sanofi, RadioMedix, and Orano Med announce licensing …
As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet medical needs in cancer, and Orano ...
Press Release: Sanofi, RadioMedix, and Orano Med announce …
Sep 12, 2005 · As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet medical needs in cancer, and Orano ...
Press Release: Sanofi and Orano join forces to develop next …
4 days ago · President of the Governing Board, Orano Med “Sanofi’s partnership with Orano Med is a strong recognition of the potential of lead-212 based radioligand therapies to advance the treatment of ...
Press Release: Sanofi and Orano join forces to develop
4 days ago · President of the Governing Board, Orano Med “Sanofi’s partnership with Orano Med is a strong recognition of the potential of lead-212 based radioligand therapies to advance the treatment of ...
Sanofi returns to Orano with €300M for new radioligand 'pioneer'
4 days ago · Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned with 300 million euros ($326 million) to set up a more ...
Sanofi and Orano Med link for radioligand therapy development
3 days ago · Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest in a new entity, operating under the brand Orano Med, which focuses on the discovery, design and development of RLTs based on lead-212 (212Pb) alpha ...
SNY Inks Deal With Orano Med for Next-Generation Radioligand …
4 days ago · The new entity will operate under the brand of Orano Med. Year to date, shares of Sanofi have increased 9.5% compared with the industry’s rise of 20.6%. Zacks Investment Research
- Some results have been removed